The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Trial of Pregabalin for Acute and Chronic Sciatica
Open accessAbstract
BACKGROUND: Sciatica can be disabling, and evidence regarding medical treatments is limited. Pregabalin is effective in the treatment of some types of neuropathic pain. This study examined whether pregabalin may reduce the intensity of sciatica. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of pregabalin in patients with sciatica. Patients were randomly assigned to receive either pregabalin at a dose of 150 mg per day that was adjusted to a maximum dose of 600 mg per day or matching placebo for up to 8 weeks. The primary outcome was the leg-pain intensity score on a 10-point scale (with 0 indicating no pain and 10 the worst possible pain) at week 8; the leg-pain intensity score was also evaluated at week 52, a secondary time point for the primary outcome. Secondary outcomes included the extent of disability, back-pain intensity, and quality-of-life measures at prespecified time points over the course of 1 year. RESULTS: A total of 209 patients underwent randomization, of whom 108 received pregabalin and 101 received placebo; after randomization, 2 patients in the pregabalin group were determined to be ineligible and were excluded from the analyses. At week 8, the mean unadjusted leg-pain intensity score was 3.7 in the pregabalin group and 3.1 in the placebo group (adjusted mean difference, 0.5; 95% confidence interval [CI], -0.2 to 1.2; P=0.19). At week 52, the mean unadjusted leg-pain intensity score was 3.4 in the pregabalin group and 3.0 in the placebo group (adjusted mean difference, 0.3; 95% CI, -0.5 to 1.0; P=0.46). No significant between-group differences were observed with respect to any secondary outcome at either week 8 or week 52. A total of 227 adverse events were reported in the pregabalin group and 124 in the placebo group. Dizziness was more common in the pregabalin group than in the placebo group. CONCLUSIONS: Treatment with pregabalin did not significantly reduce the intensity of leg pain associated with sciatica and did not significantly improve other outcomes, as compared with placebo, over the course of 8 weeks. The incidence of adverse events was significantly higher in the pregabalin group than in the placebo group. (Funded by the National Health and Medical Research Council of Australia; PRECISE Australian and New Zealand Clinical Trials Registry number, ACTRN12613000530729 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Quality of life (QoL) through the SF-12 questionnaire was assessed in one of the pregabalin trials.21 No statistical differences were found at 2, 8, 26 and 52 weeks.”
From A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain (2022) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Serious AE were similar in the pregabalin group and the placebo group21, 27 as well as in patients with one or more AE.27, 28”
From A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain (2022) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“This study focuses specifically on the use of gabapentin and pregabalin for pain associated with acute sciatica since the evidence on their use is limited.”
From A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain (2022) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Assessment of other potential sources of bias gave a low risk of bias for four studies.20, 21, 30, 31 Three were rated as unclear risk of bias28, 29, 32 and one was rated as high risk of bias27 due to a run-in period, where placebo respondents and pregabalin non-respondents were eliminated.”
From A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain (2022) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Five were double-blinded21, 27, 28, 29, 32; one was single-blinded30; and two were open label.20, 31”
From A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain (2022) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In particular as regards pregabalin, three studies compared pregabalin versus placebo21, 27, 29 and one compared limaprost versus pregabalin versus an association of both drugs in a three-arm trial.28”
From A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain (2022) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Only four studies assessed pregabalin undesirable effects.21, 27, 28, 29”
From A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain (2022) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“To our knowledge regarding their use on sciatica, pain relief only has been reported in one trial comparing gabapentin with placebo20 and in no one of those investigating pregabalin.21”
From A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain (2022) · cites this paper as [21]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Attrition bias was rated as an unclear risk for most of the trials. Three were rated as low risk of bias,21, 27, 31 and two were rated as high risk of bias.29, 32”
From A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain (2022) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980
The estimation of a preference-based measure of health from the SF-36.
Brazier, J., Roberts, J., & Deverill, M. (2002) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00130-8 · Cited by 3,164
Pain: a review of three commonly used pain rating scales
Williamson, A., & Hoggart, B. (2005) · Journal of Clinical Nursing · doi:10.1111/j.1365-2702.2005.01121.x · Cited by 3,083
Freynhagen, R., Baron, R., Gockel, U., & Tölle, T. R. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132488 · Cited by 2,280
Ostelo, R. W. J. G., Deyo, R. A., Stratford, P., Waddell, G., Croft, P., Von Korff, M., Bouter, L. M., & de Vet, H. C. (2008) · Spine · doi:10.1097/brs.0b013e31815e3a10 · Cited by 2,009
Koes, B. W., van Tulder, M. W., Lin, C. C., Macedo, L. G., McAuley, J. H., & Maher, C. G. (2010) · European Spine Journal · doi:10.1007/s00586-010-1502-y · Cited by 1,301
Self-citationThe Estimation of a Preference-Based Measure of Health From the SF-12
Brazier, J. E., & Roberts, J. (2004) · Medical Care · doi:10.1097/01.mlr.0000135827.18610.0d · Cited by 1,294
Surgery versus Prolonged Conservative Treatment for Sciatica
Peul, W. C., van Houwelingen, H. C., van den Hout, W. B., Brand, R., Eekhof, J. A., Tans, J. T. J., Thomeer, R. T. W. M., & Koes, B. W. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064039 · Cited by 864
Self-citation
Research works printed but not linked: 5
- Moore RA, 2009, Cochrane Database Syst Rev, CD007076
- Mangaiarkkarasi A, 2015, J Clin Diagn Res, 9, FF11
- Food and Drug Administration. Statistical review and evaluation: antiepileptic drugs and suicidality. Rockville, MD: Department of Health and Human Services, 2008.
- Ehrlich GE, 2003, Bull World Health Organ, 81, 671
- Bombardier C, 2001, J Rheumatol, 28, 431
Cited by
Sorted by citations
Prevention and treatment of low back pain: evidence, challenges, and promising directions
Foster, N. E., Anema, J. R., Cherkin, D., Chou, R., Cohen, S. P., Gross, D. P., Ferreira, P. H., Fritz, J. M., Koes, B. W., Peul, W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30489-6 · Cited by 2,398
Self-citationVlaeyen, J. W. S., Maher, C. G., Wiech, K., Van Zundert, J., Meloto, C. B., Diatchenko, L., Battié, M. C., Goossens, M., Koes, B., & Linton, S. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0052-1 · Cited by 497
Self-citationMoisset, X., Bouhassira, D., Avez‐Couturier, J., Alchaar, H., Conradi, S., Delmotte, M. H., Lantéri‐Minet, M., Lefaucheur, J. P., Mick, G., Piano, V., et al. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.01.361 · Cited by 458
Pregabalin for neuropathic pain in adults
Derry, S., Bell, R. F., Straube, S., Wiffen, P. J., Aldington, D. J., & Moore, A. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007076.pub3 · Cited by 386
Gabapentin and Pregabalin for Pain — Is Increased Prescribing a Cause for Concern?
Goodman, C. W., & Brett, A. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1704633 · Cited by 343
A Clinical Overview of Off-label Use of Gabapentinoid Drugs
Goodman, C. W., & Brett, A. S. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0086 · Cited by 232
Therapeutic Approaches for Peripheral and Central Neuropathic Pain
Szok, D., Tajti, J., Nyári, A., Vécsei, L., & Trojano, L. (2019) · Behavioural Neurology · doi:10.1155/2019/8685954 · Cited by 220
Gabapentinoid Use in the United States 2002 Through 2015
Johansen, M. E. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.7856 · Cited by 199
Enke, O., New, H. A., New, C. H., Mathieson, S., McLachlan, A. J., Latimer, J., Maher, C. G., & Lin, C.-W. C. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.171333 · Cited by 192
Self-citationVA/DoD Clinical Practice Guideline: Diagnosis and Treatment of Low Back Pain
Pangarkar, S. S., Kang, D. G., Sandbrink, F., Bevevino, A. J., Tillisch, K., Konitzer, L. N., & Sall, J. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05086-4 · Cited by 172
Nonnarcotic Methods of Pain Management
Finnerup, N. B. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1807061 · Cited by 153
Diagnosis and management of low-back pain in primary care
Traeger, A. C., Buchbinder, R., Harris, I. A., & Maher, C. G. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170527 · Cited by 153
Self-citationOnakpoya, I. J., Thomas, E. T., Lee, J. J., Goldacre, B., & Heneghan, C. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023600 · Cited by 132
Molero, Y., Larsson, H., D'Onofrio, B. M., Sharp, D. J., & Fazel, S. (2019) · BMJ · doi:10.1136/bmj.l2147 · Cited by 130
Macrophage angiotensin II type 2 receptor triggers neuropathic pain
Shepherd, A. J., Mickle, A. D., Golden, J. P., Mack, M. R., Halabi, C. M., de Kloet, A. D., Samineni, V. K., Kim, B., Krause, E. G., Gereau, R. W., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721815115 · Cited by 126
Nijs, J., Kosek, E., Chiarotto, A., Cook, C. E., Danneels, L. A., Fernández‐de‐las‐Peñas, C., Hodges, P. W., Koes, B. W., Louw, A., Ostelo, R., et al. (2024) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00324-7 · Cited by 136
Self-citationChadwick, A. L., Hurley, R. W., & Benzon, H. T. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002426 · Cited by 110
Fabritius, M. L., Strøm, C., Koyuncu, S., Jæger, P., Petersen, P. L., Geisler, A. E., Wetterslev, J., Dahl, J. B., & Mathiesen, O. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aex227 · Cited by 84
Robertson, K., Marshman, L. A. G., Plummer, D., & Downs, E. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3077 · Cited by 82
Katz, N. P., Dworkin, R. H., North, R. B., Thomson, S., Eldabe, S. S., Hayek, S. M., Kopell, B. H., Markman, J. D., Rezai, A. R., Taylor, R. S., et al. (2021) · Pain · doi:10.1097/j.pain.0000000000002204 · Cited by 74
Radicular Pain Syndromes: Cervical, Lumbar, and Spinal Stenosis
Patel, E., & Perloff, M. D. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1673680 · Cited by 72
Informed appropriate imaging for low back pain management: A narrative review
Wáng, Y. X. J., Wu, A., Santiago, F. R., & Nogueira‐Barbosa, M. H. (2018) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2018.07.009 · Cited by 69
Taneja, A., Pasqua, O. E. D., & Danhof, M. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2301-8 · Cited by 60
Research progress of mechanisms and drug therapy for neuropathic pain
Yan, Y., Li, C.-Y., Zhou, L., Ao, L., Fang, W., & Li, Y. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.09.033 · Cited by 57
2018 Update on Medical Overuse
Morgan, D. J., Dhruva, S. S., Coon, E. R., Wright, S. M., & Korenstein, D. R. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.5748 · Cited by 57
Tu, J.-F., Shi, G.-X., Yan, S.-Y., Ni, G.-X., Yu, F.-T., Cai, G.-W., Liu, Z.-S., Ma, C.-Y., Wang, L.-Q., Yang, J.-W., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.5463 · Cited by 54
Peene, L., Cohen, S. P., Kallewaard, J. W., Wolff, A. P., Huygen, F. J. P. M., van der Gaag, A., Steegers, M. A. H., Vissers, K. C. P., Gilligan, C. J., Zundert, J. H. M. V., et al. (2023) · Pain Practice · doi:10.1111/papr.13317 · Cited by 55
Schmid, A. B., Tampin, B., Baron, R., Finnerup, N. B., Hansson, P., Hietaharju, A., Konstantinou, K., Lin, C.-W. C., Markman, J., Price, C., et al. (2023) · Pain · doi:10.1097/j.pain.0000000000002919 · Cited by 51
Self-citationPharmacotherapy for Spine-Related Pain in Older Adults
Fu, J. L., & Perloff, M. D. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00946-x · Cited by 52
Giménez-Campos, M. S., Pimenta-Fermisson-Ramos, P., Díaz-Cambronero, J. I., Carbonell-Sanchís, R., López-Briz, E., & Ruíz-García, V. (2022) · Atención Primaria · doi:10.1016/j.aprim.2021.102144 · Cited by 50
“D íaz-Cam bronero et al. Table 1 (Continued) First author; year of publication Design Participant selection criteria Interventions Outcomes Randomized, double blind, placebo-controlled trial.”
InfluentialPharmacological and non-pharmacological treatment approaches to chronic lumbar back pain
Ketenci, A. (2021) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2021.8216 · Cited by 57
Gorfinkel, L., Hasin, D. S., Saxon, A. J., Wall, M. M., Martins, S. S., Cerdá, M., Keyes, K. M., Fink, D. S., Keyhani, S., Maynard, C. C., et al. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.01.006 · Cited by 47
Pregabalin prescribing patterns in Australian general practice, 2012–2018: a cross-sectional study
Schaffer, A. L., Busingye, D., Chidwick, K., Brett, J., & Blogg, S. (2020) · BJGP Open · doi:10.3399/bjgpopen20x101120 · Cited by 44
Non-Invasive and Minimally Invasive Management of Low Back Disorders
Hegmann, K. T., Travis, R. L., Andersson, G. B. J., Belcourt, R. M., Carragee, E. J., Donelson, R. G., Eskay-Auerbach, M., Galper, J. S., Goertz, M., Haldeman, S., et al. (2020) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000001812 · Cited by 38
Gatzinsky, K. P., Eldabe, S. S., Deneuville, J.-P., Duyvendak, W., Naïditch, N., Buyten, J. V., & Rigoard, P. (2019) · Pain Research and Management · doi:10.1155/2019/8184592 · Cited by 39
Giovanardi, C. M., González‐Lorenzo, M., Poini, A., Marchi, E., Culcasi, A., Ursini, F., Faldini, C., Martino, A. C. D., Mazzanti, U., Campesato, M., et al. (2023) · Integrative Medicine Research · doi:10.1016/j.imr.2023.100972 · Cited by 39
The case for cautious consumption
Sriperumbuduri, S., & Hiremath, S. S. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000473 · Cited by 36
The need for better access to pain treatment: learning from drug consumption trends in the USA
Scuteri, D. (2017) · Functional Neurology · doi:10.11138/fneur/2017.32.4.229 · Cited by 35
Kersten, C., Cameron, M. G., Bailey, A., Fallon, M., Laird, B. J. A., Paterson, V., Mitchell, R., Fleetwood‐Walker, S., Daly, F., & Mjåland, S. (2019) · Pain Medicine · doi:10.1093/pm/pnz101 · Cited by 35
Common Clinical Practice for Low Back Pain Treatment: A Modified Delphi Study
Varrassi, G., Moretti, B., Pace, M. C., Evangelista, P., & Iolascon, G. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00249-w · Cited by 35
Sharma, S., Jensen, M. P., Moseley, G. L., & Abbott, J. H. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022423 · Cited by 33
de Landaluce, L. O., Carbonell‐Mirabent, P., Asensio, C., Escoda, N., López, P., & Laporte, J. (2018) · Drug Safety · doi:10.1007/s40264-018-0695-6 · Cited by 33
Huon, J., Sanyal, C., Gagnon, C. L., Turner, J. P., Khuong, N. B., Bortolussi‐Courval, É., Lee, T. C., Silvius, J. L., Morgan, S. G., & McDonald, E. G. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19164 · Cited by 36
Developing Modern Pain Therapies
Manion, J., Waller, M. A., Clark, T., Massingham, J. N., & Neely, G. G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01370 · Cited by 35
Taguchi, T., Nakano, S., & Nozawa, K. (2021) · Journal of Pain Research · doi:10.2147/jpr.s293556 · Cited by 30
Resorption of Lumbar Disk Herniation
Hornung, A. L., Baker, J. D., Mallow, G. M., Sayari, A. J., Albert, H., Tkachev, A., An, H. S., & Samartzis, D. (2023) · JBJS Reviews · doi:10.2106/jbjs.rvw.22.00148 · Cited by 30
Statistical analyses of ordinal outcomes in randomised controlled trials: a scoping review
Selman, C. J., Lee, K. J., Ferguson, K. N., Whitehead, C. L., Manley, B. J., & Mahar, R. K. (2024) · Trials · doi:10.1186/s13063-024-08072-2 · Cited by 32
Treatment Gaps and Emerging Therapies in Lumbar Disc Herniation
Beall, D. P., Kim, K. D., Macadaeg, K. E., Donboli, K., Chauhan, K., Sowlay, M., Guo, A. X., & Vaccaro, A. R. (2024) · Pain Physician · doi:10.36076/ppj.2024.27.401 · Cited by 30
Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications
Federico, C. A., Wang, T., Doussau, A., Mogil, J. S., Fergusson, D. A., & Kimmelman, J. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.5705 · Cited by 31
Management of Chronic Low Back Pain
Cohen, K. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7359 · Cited by 30
Dillingham, T. R., Annaswamy, T. M., & Plastaras, C. T. (2020) · Muscle & Nerve · doi:10.1002/mus.26997 · Cited by 29
Diagnosis and Management of Neuropathic Pain in Spine Diseases
Bielewicz, J., Kamieniak, M., Szymoniuk, M., Litak, J., Czyżewski, W., & Kamieniak, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041380 · Cited by 29
Williams, C. D., Al-jammali, Z., & Herink, M. C. (2022) · Drugs · doi:10.1007/s40265-022-01810-3 · Cited by 28
Tapentadol: an effective option for the treatment of back pain
Coluzzi, F., Polati, E., Freo, U., & Grilli, M. (2019) · Journal of Pain Research · doi:10.2147/jpr.s190176 · Cited by 28
Prescribing practice of pregabalin/gabapentin in pain therapy: an evaluation of German claim data
Viniol, A., Ploner, T., Hickstein, L., Haasenritter, J., Klein, K. M., Walker, J., Donner‐Banzhoff, N., & Becker, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-021535 · Cited by 28
Albert, H., Sayari, A. J., Barajas, J. N., Hornung, A. L., Harada, G. K., Nolte, M. T., Chee, A., Samartzis, D., & Tkachev, A. (2023) · European Spine Journal · doi:10.1007/s00586-023-08064-x · Cited by 28
Hasvik, E., Haugen, A. J., Gjerstad, J., & Grøvle, L. (2018) · European Journal of Pain · doi:10.1002/ejp.1204 · Cited by 27
Aminophylline for treatment of postdural puncture headache
Wu, C., Guan, D., Ren, M., Zheng-fei, M., Wan, C., Cui, Y., Zhong, P., Zhao, W., Li, C., Yan, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005351 · Cited by 27
Shirado, O., Arai, Y., Iguchi, T., Imagama, S., Kawakami, M., Nikaido, T., Ogata, T., Orita, S., Sakai, D., Sato, K., et al. (2021) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2021.06.024 · Cited by 28
Appleyard, T., Ashworth, J., Bedson, J., Yu, D., & Peat, G. (2019) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2019.06.008 · Cited by 31
Hansford, H. J., Jones, M. D., Cashin, A. G., Ostelo, R., Chiarotto, A., Williams, S. A., Sharma, S., Devonshire, J. J., Ferraro, M. C., Wewege, M. A., et al. (2023) · Journal of physiotherapy · doi:10.1016/j.jphys.2023.08.006 · Cited by 26
Ongoing challenges of off-label prescribing
Day, R. O. (2023) · Australian Prescriber · doi:10.18773/austprescr.2023.022 · Cited by 26
Self-citationParfenov, V. A., Yakhno, N. N., Давыдов, О. С., Kukushkin, M. L., Churyukanov, M. V., Golovacheva, V. A., Evzikov, G. Y., Isaikin, A. I., Ivanova, M. A., Karateev, A. E., et al. (2020) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2020-4-15-24 · Cited by 26
Lynn, E. C., Cousins, G., Lyons, S., & Bennett, K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107741 · Cited by 27
Jesson, T., Runge, N., & Schmid, A. B. (2020) · PAIN Reports · doi:10.1097/pr9.0000000000000834 · Cited by 25
Gabapentinoids: a therapeutic review
Athavale, A., & Murnion, B. P. (2023) · Australian Prescriber · doi:10.18773/austprescr.2023.025 · Cited by 24
Napoli, A., Alfieri, G., Maio, A. D., Panella, E., Scipione, R., Facchini, G., Albisinni, U., Spinnato, P., Nardis, P., Tramutoli, R., et al. (2023) · Radiology · doi:10.1148/radiol.221478 · Cited by 22
Ramaswami, R., Ghogawala, Z., & Weinstein, J. N. (2017) · New England Journal of Medicine · doi:10.1056/nejmclde1701008 · Cited by 24
Analgesia for non-specific low back pain
Jones, C. M. P., Underwood, M., Chou, R., Schoene, M., Sabzwari, S., Cavanagh, J., & Lin, C.-W. C. (2024) · BMJ · doi:10.1136/bmj-2024-080064 · Cited by 21
Self-citationGérard, B., Bailly, F., & Trouvin, A. (2023) · Joint Bone Spine · doi:10.1016/j.jbspin.2023.105624 · Cited by 23
Foster, N. E., Konstantinou, K., Lewis, M., Ogollah, R. O., Saunders, B., Kigozi, J., Jowett, S. M., Bartlam, B., Artus, M., Hill, J. C., et al. (2020) · Health Technology Assessment · doi:10.3310/hta24490 · Cited by 20
A systematic review and meta-analysis of pregabalin preclinical studies
Federico, C. A., Mogil, J. S., Ramsay, T., Fergusson, D. A., & Kimmelman, J. (2020) · Pain · doi:10.1097/j.pain.0000000000001749 · Cited by 20
Dillingham, T. R., Annaswamy, T. M., & Plastaras, C. T. (2020) · Muscle & Nerve · doi:10.1002/mus.27008 · Cited by 18
Hansford, H. J., Jones, M. D., Cashin, A. G., Ostelo, R., Chiarotto, A., Williams, S. A., Sharma, S., Rose, J. M., Devonshire, J. J., Ferraro, M. C., et al. (2024) · Journal of Orthopaedic and Sports Physical Therapy · doi:10.2519/jospt.2024.12279 · Cited by 18
Trial of Pregabalin for Acute and Chronic Sciatica
Kosugi, K., Tagami, K., & Tanimoto, T. E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705241 · Cited by 18
Pregabalin: a better neuropathic pain treatment in rodents than in humans
Moisset, X., Pereira, B., Bouhassira, D., & Attal, N. (2020) · Pain · doi:10.1097/j.pain.0000000000001993 · Cited by 18
Miyawaki, A., Ikesu, R., Tokuda, Y., Goto, R., Kobayashi, Y., Sano, K., & Tsugawa, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063171 · Cited by 17
Safari, M. B., Nozad, A., Ghaffari, F., Ghavamzadeh, S., Alijaniha, F., & Naseri, M. (2020) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2019.0360 · Cited by 16
Koshimizu, H., Ohkawara, B., Nakashima, H., Ota, K., Kanbara, S., Inoue, T., Tomita, H., Sayo, A., Kiryu‐Seo, S., Konishi, H., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118577 · Cited by 16
Gabapentinoids: The rise of a new misuse epidemics?
Hofmann, M., & Besson, M. J. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114193 · Cited by 19
Comparative Efficacy of Pharmacological Therapies for Low Back Pain: A Bayesian Network Analysis
Jiang, J., Pan, H., Chen, H., Song, L., Wang, Y., Qian, B., Chen, P., Fan, S., & Lin, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.811962 · Cited by 15
Price, M. R., Mead, K. E., Cowell, D. M., Troutner, A. M., Barton, T. E., Walters, S., & Daniels, C. J. (2024) · PM&R · doi:10.1002/pmrj.13142 · Cited by 15
ter Meulen, B. C., Overweg, C., Feenstra, T. C., Brouwer, B. A., Terheggen, M. A. M. B., van Dongen, H., Kallewaard, J. W., Ostelo, R., & Weinstein, H. C. (2021) · European Neurology · doi:10.1159/000515578 · Cited by 14
Nikles, J., Keijzers, G., Mitchell, G. K., Farrell, S. F., Perez, S., Schug, S. A., Ware, R. S., McLean, S. A., Connelly, L. B., & Sterling, M. M. (2021) · Pain · doi:10.1097/j.pain.0000000000002362 · Cited by 14
Assessment and nonsurgical management of low back pain: a narrative review
Park, S. C., Kang, M., Yang, J. H., & Kim, T.-H. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.250 · Cited by 17
Ferreira, G. E., Zadro, J. R., Jones, C. M. P., Ayre, J., Lin, C. C., Richards, B. L., Needs, C., Shaheed, C. A., McLachlan, A. J., Day, R. O., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-074380 · Cited by 13
Self-citationSharif, S. Y., Ali, M. Y. J., Kirazlı, Y., Vlok, I., Zygourakis, C. C., & Zileli, M. (2024) · World Neurosurgery X · doi:10.1016/j.wnsx.2024.100273 · Cited by 13
Is Pregabalin Effective Against Acute Lumbar Radicular Pain ?
Nakashima, H., Kanemura, T., Ando, K., Kobayashi, K., Yoneda, M., Ishiguro, N., & Imagama, S. (2018) · Spine Surgery and Related Research · doi:10.22603/ssrr.2018-0003 · Cited by 13
Nakajima, H., Watanabe, S., Honjoh, K., Kubota, A., & Matsumine, A. (2024) · Spine Surgery and Related Research · doi:10.22603/ssrr.2023-0294 · Cited by 12
Shaheed, C. A., Maher, C. G., Buchbinder, R., Ng, B. C. K., Enke, O., Guzowski, R., McLachlan, A. J., Day, R. O., Richards, B. L., Latimer, J., et al. (2019) · European Journal of Pain · doi:10.1002/ejp.1505 · Cited by 12
Self-citationKe, C., You, X., Lin, C., Chen, J., Guo, G., Wu, W., Ye, L., & Huang, P. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.10.026 · Cited by 12
Self-citationDeprescribing interventions for gabapentinoids in adults: A scoping review
Anderson, P. A., McLachlan, A. J., Shaheed, C. A., Gnjidic, D., Ivers, R. G., & Mathieson, S. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15798 · Cited by 12
Self-citationTaguchi, T., Nozawa, K., Parsons, B., Yoshiyama, T., Ebata, N., Igarashi, A., & Fujii, K. (2019) · Journal of Pain Research · doi:10.2147/jpr.s191906 · Cited by 11
Wilby, M. J., Hopkins, C., Bedson, E., Howlin, S., Burnside, G., Conroy, E. J., Hughes, D. A., Sharma, M. L., Marson, A. G., Clark, S., et al. (2018) · Trials · doi:10.1186/s13063-018-2677-5 · Cited by 11
Gewandter, J. S., Frazer, M. E., Cai, X., Chiodo, V. F., Rast, S. A., Dugan, M. M., Carter, H. A., Rahmani, R., Stone, J. J., & Markman, J. D. (2019) · Pain · doi:10.1097/j.pain.0000000000001478 · Cited by 11
Zhao, D., Baek, J., Hume, A. L., McPhillips, E. A., & Lapane, K. L. (2022) · Journal of Pain Research · doi:10.2147/jpr.s345521 · Cited by 10
Grace, S., Engel, R. M., & Jalsion, I. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/2786106 · Cited by 10
Edamura, T., Sumitani, M., Hayakawa, K., Inoue, R., Abe, H., Tsuchida, R., Chikuda, H., Ogata, T., Kurano, M., Aoki, J., et al. (2022) · Pain and Therapy · doi:10.1007/s40122-022-00445-2 · Cited by 10
Patterns of pregabalin initiation and discontinuation after its subsidy in Australia
Chiu, T., Brett, J., Pearson, S., & Schaffer, A. L. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14276 · Cited by 10
Tagami, K., Matsuoka, H., Ariyoshi, K., Oyamada, S., Hiratsuka, Y., Kizawa, Y., Koyama, A., & Inoue, A. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa147 · Cited by 10
Metadata
- Authors
- Mathieson, S., Maher, C. G., McLachlan, A. J., Latimer, J., Koes, B. W., Hancock, M. J., Harris, I., Day, R. O., Billot, L., Pik, J., Jan, S., & Lin, C.-W. C.
- Affiliations
- The University of Sydney (AU)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-23
- Volume
- 376
- Issue
- 12
- Pages
- 1111-1120
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2600085695
- Cited by
- 219
- References
- 32
- Citations by year
- 2026: 17 · 2025: 15 · 2024: 22 · 2023: 23 · 2022: 16 · 2021: 19 · 2020: 28 · 2019: 30 · 2018: 32 · 2017: 17
- FWCI
- 20.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- The Sydney eScholarship Repository (The University of Sydney) (submittedVersion)
- Funders
- Pfizer
- GlaxoSmithKline
- GlaxoSmithKline Australia
- Medical Research Council
- National Health and Medical Research Council (1042073)
- Topics
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Musculoskeletal pain and rehabilitation
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Spine and Intervertebral Disc Pathology
- Keywords
- sciatica, pregabalin, leg pain, neuropathic pain, pain intensity, disability, back pain, quality of life, adverse events, dizziness, drug efficacy, placebo comparison, chronic sciatica, acute sciatica, lumbar radiculopathy, drug safety, dose adjustment, adverse drug reactions
- MeSH terms
- Pregabalin, Adult, Aged, Analgesics, Back Pain, Disability Evaluation, Dizziness, Double-Blind Method, Female, Humans, Male, Middle Aged, Pain Measurement, Quality of Life, Sciatica, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
